Cargando…

Ipilimumab in patients with melanoma and autoimmune disease

Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), an immune-checkpoint receptor and regulator of T-cell activation, has become an important therapeutic target for immunotherapy in cancer and autoimmune diseases. To date, clinical trials involving cancer immunotherapies, such checkpoint blocking antibodies...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kyi, Chrisann, Carvajal, Richard D, Wolchok, Jedd D, Postow, Michael A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207313/ https://www.ncbi.nlm.nih.gov/pubmed/25349698 http://dx.doi.org/10.1186/s40425-014-0035-z

Ejemplares similares

Opportunistic infections in patients treated with immunotherapy for cancer
por: Kyi, Chrisann, et al.
Publicado: (2014)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

T cell receptor diversity evaluation to predict patient response to Ipilimumab in metastatic melanoma
por: Postow, Michael, et al.
Publicado: (2014)

Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma
por: Postow, Michael A., et al.
Publicado: (2015)

Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment()
por: Cassidy, Michael R., et al.
Publicado: (2017)

Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma
por: Homicsko, Krisztian, et al.
Publicado: (2022)

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
por: Ku, Geoffrey Y, et al.
Publicado: (2010)

Patterns of long-term survival following Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience
por: Page, David B, et al.
Publicado: (2014)

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
por: Rosner, Samuel, et al.
Publicado: (2018)

Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation
por: Morales, Rita E, et al.
Publicado: (2015)

Ipilimumab-Induced Neutropenia in Melanoma
por: Ban-Hoefen, Makiko, et al.
Publicado: (2016)

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab
por: Postow, Michael A, et al.
Publicado: (2014)

A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma
por: Slingluff, Craig L., et al.
Publicado: (2021)

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
por: Wolchok, Jedd D, et al.
Publicado: (2013)

Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma
por: Kraehenbuehl, Lukas, et al.
Publicado: (2022)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
por: Callahan, Margaret K., et al.
Publicado: (2015)

Pre-treatment serum vascular endothelial growth factor is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab
por: Yuan, Jianda, et al.
Publicado: (2013)

Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses
por: Friedman, Claire F, et al.
Publicado: (2022)

Treatment of Ipilimumab Induced Graves' Disease in a Patient with Metastatic Melanoma
por: Azmat, Umal, et al.
Publicado: (2016)

Immuno-oncology safety education experience: Key lessons from ipilimumab (IPI)
por: Bartell, Heddy, et al.
Publicado: (2015)

Acute visual loss after ipilimumab treatment for metastatic melanoma
por: Wilson, Melissa A., et al.
Publicado: (2016)

Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment
por: Anderson, Erik S., et al.
Publicado: (2017)

A Patient with HIV Treated with Ipilimumab and Stereotactic Radiosurgery for Melanoma Metastases to the Brain
por: Ruzevick, Jacob, et al.
Publicado: (2013)

Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
por: Hantel, Andrew, et al.
Publicado: (2018)

Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid
por: Beck, Kristen M., et al.
Publicado: (2016)

Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report
por: Meyers, D. E., et al.
Publicado: (2018)

Grover’s-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy
por: Koelzer, Viktor H., et al.
Publicado: (2016)

Bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma
por: Hanley, T, et al.
Publicado: (2018)

Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma
por: Jeter, Joanne M., et al.
Publicado: (2012)

Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis
por: Bello, Elisa, et al.
Publicado: (2019)

Complete regression of mycosis fungoides after ipilimumab therapy for advanced melanoma
por: Bar-Sela, Gil, et al.
Publicado: (2015)

Ipilimumab: Melanoma and beyond
por: Patel, Vishal, et al.
Publicado: (2011)

Paraneoplastic hyperleucocytosis in a melanoma patient after initiation of ipilimumab and nivolumab combination therapy
por: Gambichler, Thilo, et al.
Publicado: (2018)

Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib
por: Chapman, Paul B., et al.
Publicado: (2023)

The delicate balance of melanoma immunotherapy
por: Gyorki, David E, et al.
Publicado: (2013)

Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors
por: Mamoor, Maha, et al.
Publicado: (2020)

Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod
por: Fujimura, Taku, et al.
Publicado: (2018)

Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience
por: Karivedu, Vidhya, et al.
Publicado: (2019)

Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition—A Pooled Analysis of Patients With Advanced Melanoma
por: Regan, Meredith M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4qp8glhsl5aqik6c4ok950do6q